Repositorio Dspace

Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE

Mostrar el registro sencillo del ítem

dc.contributor.author Puente, Javier
dc.contributor.author Anido, Javier-C
dc.contributor.author Climent, Miguel-Ángel
dc.contributor.author González-Billalabeitia, Enrique
dc.contributor.author Lainez, Nuria
dc.contributor.author Lambea, Julio
dc.contributor.author Maroto, José-Pablo
dc.contributor.author Méndez-Vidal, María-José
dc.contributor.author Montesa, Álvaro
dc.contributor.author Rodríguez, Ángel
dc.contributor.author Zambrana, Curro
dc.contributor.author González-del-Alba, Aranzazu
dc.date.accessioned 2025-11-20T07:13:06Z
dc.date.available 2025-11-20T07:13:06Z
dc.date.issued 2020-05
dc.identifier.citation Puente J, Anido U, Climent MÁ, Gonzalez-Billalabeitia E, Lainez N, Lambea J, et al. Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE. Ther Adv Med Oncol. enero de 2020;12:1758835920920067.
dc.identifier.issn 1758-8340
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/21440
dc.description.abstract OBJECTIVE: Our aim was to provide practical recommendations on the management of patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel plus androgen-deprivation therapy (ADT) or abiraterone plus ADT. METHODS: Systematic literature review (SLR), nominal group meeting, and Delphi process. A panel of 12 experts was established who defined the scope, users, and sections of the document. We performed an SLR in order to assess the efficacy and safety of available drugs in patients with mCRPC. Abstracts from the American Society of Oncology and European Society for Medical Oncology meetings were also examined. The results were discussed during an expert meeting in which 14 recommendations were generated. The level of agreement with the recommendations was also tested by 13 additional experts following the Delphi process. Recommendations were voted by means of scores ranging from 0 (total disagreement) to 10 (total agreement). We defined agreement when at least 70% of the experts voted ?7. Next, we assigned a level of evidence and grade to the recommendation using the Oxford Centre for Evidence-based Medicine Levels of Evidence, following which the final document was drafted. RESULTS: The literature search did not find any articles meeting the inclusion criteria. Finally, 13 out of 14 recommendations were accepted after two Delphi rounds (two were modified after the first round). They pertain to general and individual case-based treatment recommendations. CONCLUSIONS: In mCRPC patients who have progressed after docetaxel or abiraterone plus ADT in the metastatic hormone-sensitive prostate cancer setting, these recommendations may support treatment decision-making, due to the lack of evidence or other globally accepted sequencing algorithms.
dc.language.iso eng
dc.publisher SAGE PUBLICATIONS LTD
dc.rights http://creativecommons.org/licenses/by-nc-nd/3.0/es/
dc.rights.uri Atribución-NoComercial-SinDerivadas 3.0 España *
dc.title Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE
dc.type info:eu-repo/semantics/article
dc.identifier.pmid 33014145
dc.relation.publisherversion https://journals.sagepub.com/doi/10.1177/1758835920920067
dc.identifier.doi 10.1177/1758835920920067
dc.journal.title Therapeutic Advances in Medical Oncology
dc.identifier.essn 1758-8359


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta